Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project26.3.2026 22:00:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / March 26, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to provide an update on its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Company Financing update The Company has been approved for up to $200,000 in government funding as part of the Ontario Junior Exploration Program (OJEP) that will be used to advance work in the 2.5 km long Escape down-plunge target, where it recently intersected 53m of resource-grade mineralization in the initial exploration hole (Figure 1 and October 20, 2025 release). "Ontario is leading the charge to secure the minerals that will power our economy and strengthen our sovereignty," said Stephen Lecce, Minister of Energy and Mines. "Through OJEP, we're backing companies like Clean Air Metals Inc. to advance promising projects here at home-unlocking resources, creating jobs, and building a more self-reliant and secure
LHH 2026 C-Suite Research: Executive Turnover Falls Sharply as AI Accountability and Decision-Making Gaps Define Leadership Agenda26.3.2026 17:05:00 CET | Press release
High-turnover leadership teams drop from 43% to 19% year-over-year; AI identified as the #1 executive skill gap. NEW YORK CITY, NY / ACCESS Newswire / March 26, 2026 / LHH, the integrated professional talent solutions provider and global business unit of the Adecco Group, released its 2026 View from the C-Suite report, examining executive priorities, leadership skill gaps, and organizational performance internationally. The report highlights a notable shift in the executive landscape: while turnover is falling, the expectations and pressures on leaders are intensifying across technology, decision-making, and talent strategy. Brief The annual View from the C-Suite report finds that executive turnover is declining significantly. Leaders are navigating high external pressures, including economic uncertainty, market volatility, inflation, rising costs, and heightened data security risks. Internal priorities are increasingly focused on talent retention, team effectiveness, and employee well
Multi-Billion-Dollar Sports Brand U.S. Polo Assn. Launches Global Polo Shirt Campaign: An Icon Born from the Game26.3.2026 12:00:00 CET | Press release
WEST PALM BEACH, FLA. / ACCESS Newswire / March 26, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.1. U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the Game 2. U.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina 3. ‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. models The polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for wh
U.S. Mined and Refined Metals as well as Rare Earth Elements to Be Tokenized in Historic American Strategic Minerals and Datavault AI Deal26.3.2026 11:07:00 CET | Press release
Partnership Sets the Stage for the Launch of an International Elements Exchange Powered by Patented AI Platform Datavault AI and American Strategic Minerals debut minting of up to $2 billion USD of refined Antimony-backed stable coins will be followed by the strategic development of future projects in silver, gold, and other American refined Rare Earth Elements the companies have targeted for expansion PHILADELPHIA, PA AND LAS VEGAS, NV / ACCESS Newswire / March 26, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, and American Strategic Minerals Inc. ("ASMI"), today announced a strategic partnership to develop and monetize one of ASMI's resource extraction projects in Arizona through a $78.2 million digital tokenization initiative, with Datavault AI entitled to earn up to a 20% equity interest in ASMI upon successful completion of performa
Stagwell Expands the Harris Poll's Harrisquest Across Europe26.3.2026 11:00:00 CET | Press release
Expanding always-on brand and reputation tracking with deeper consumer insights across Europe LONDON, GB / ACCESS Newswire / March 26, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the European expansion of The Harris Poll's HarrisQuest, bringing deeper always-on, brand and reputation tracking capabilities to Europe. This expansion brings HarrisQuest's trusted brand intelligence to Europe, extending capabilities already relied on by global companies like Lucid Motors, Storck, and Post Consumer Brands to inform critical brand decisions. Now, European brands and teams can access the same high-quality data, flexible and customizable platform, and global scale spanning 24 countries to guide strategy with greater speed and confidence. Built by researchers for enterprise growth, HarrisQuest delivers continuous, decision-ready insight designed to support modern brand decision-making. The platform uniquely combines brand health
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom